NL-OMON26668
Recruiting
Not Applicable
A multicenter, double blind placebo controlled randomized trial for Benign esophageal Anastomotic Strictures: Savary dilation vs savary dilation with TriAmcinolon.
Maag-, darm-, leverziekten UMC Utrecht0 sites60 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Patients with dysphagia after esophagectomy with cervical anastomosis due to a benign anastomotic stricture.Patienten met dysfagie na een buismaagreconstructie na slokdarmresectie met een cervicale anastomose veroorzaakt door een benigne anastomotische strictuur
- Sponsor
- Maag-, darm-, leverziekten UMC Utrecht
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients with dysphagia grade 2\-4 (Atkinson Dysphagia score) after esophagectomy with gastric tube reconstruction and cervical anastomosis;
- •2\. Signed informed consent.
Exclusion Criteria
- •1\. Previous dilation;
- •2\. Dysphagia due to (suspicion of) malignant tumour recurrence;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Pediatric Formulation of bosentan in pulmonary arterial hypertension.NL-OMON20918ACTELION Pharmaceuticals LtdGewerbestrasse 16CH-4123 AllschwilSwitzerland30
Completed
Phase 2
A multicentre, double blind, placebo controlled, dose - finding clinical study for three doses of Antiadipositum X 112 T (Cathine-hydrochloride) vs. placebo in 240 patients with a body mass index (BMI) between 27 kg/m2 and 40 kg/m2E66.00DRKS00000543RIEMSER Arzneimittel AG241
Active, not recruiting
Not Applicable
A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Standard of Care.-----------------------------------------------------------------------------------------------Estudio multicéntrico, doble ciego, controlado con placebo y aleatorizado de TroVax? frente a placebo en el tratamiento de primera línea de pacientes con cáncer colorrectal metastásico que reciben el tratamiento habitual. - FLAMENCOMetastatic Colorectal Adenocarcinoma.-----------------------------------------------Adenocarcinoma Colorectal Metastásico.MedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2007-005639-26-ESOxford BioMedica1,300
Active, not recruiting
Not Applicable
A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Chemo-based Therapy. - FLAMENCOMetastatic Colorectal AdenocarcinomaMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2007-005639-26-DEOxford BioMedica (UK) Limited1,312
Active, not recruiting
Phase 1
A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Chemo-based Therapy. - FLAMENCOMetastatic Colorectal AdenocarcinomaMedDRA version: 9.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancerEUCTR2007-005639-26-GBOxford BioMedica1,312